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Abstract: Alemtuzumab is a humanized anti-CD52 monoclonal antibody used for the treatment of high activity relapsing 
multiple sclerosis (R-MS).
 
The most common adverse event is an infusion reaction due to cytokine-release. Autoimmunity can 
arise from months to years after treatment and encompasses Grave’s disease and thrombocytopenia. Recent reports of stroke, 
heart attack, and arterial dissection after alemtuzumab administration, in some cases within hours of infusion, led the European 
Medicines Agency’s (EMA's) Pharmacovigilance Risk Assessment Committee (PRAC) to a safety review of treatment with 
alemtuzumab. We report a D-Dimer increasing with suspected associated pulmonary embolism in an RMS patient after the first 
alemtuzumab administration. D-dimer test is not mandatory after alemtuzumab treatment, but its possible increase should warn 
the physician to select the patients with lower cardiovascular and thrombosis risk. 
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1. Introduction 
Alemtuzumab is a humanized monoclonal antibody 
targeting the CD52 antigen, expressed mostly on T and B 
lymphocytes surface and in a less extent on natural killer (NK) 
cells, monocytes, and dendritic cells [1], approved for the 
treatment of relapsing multiple sclerosis (R-MS). A few 
minutes after infusion of a single alemtuzumab dose, 
peripheral lymphocytes are depleted, probably as a 
consequence of antibody-dependent, cell-mediated 
cytotoxicity [2]. Cross-linking of NK cells determines the 
increase of serum cytokines, including tumor necrosis factor 
(TNF)-α, interleukin (IL)-6, and interferon (IFN)-γ [3], with 
consequent infusion-associated reaction (IAR). Pre-treatment 
with high dose corticosteroids for the first 3 days and 
antihistamine drugs is prescribed to reduce IAR symptoms, 
such as fever and cutaneous rush [4]. Other side effects 
encompass infections and autoimmunity reactions, mainly 
versus thyroid (Graves Basedow disease), kidney 
(Goodpasture syndrome) and platelets (autoimmune 
thrombocytopenia), which can occur months or even years 
after alemtuzumab treatment [1]. IAR-related cardiac 
alterations such as tachycardia, bradycardia and palpitations 
are rare [1]. Recently, reports of stroke, heart attack, and 
arterial dissection after alemtuzumab administration, in some 
cases within few hours after infusion, led the European 
Medicines Agency's (EMA's) Pharmacovigilance Risk 
Assessment Committee (PRAC) to restrict the use of 
alemtuzumab to adults with highly active R-MS, despite 
treatment with at least two disease-modifying therapies or 
where other disease-modifying therapies cannot be used [5]. 
As of March 18, 2019 D-dimer increased is reported only 
by 3 patients treated with alemtuzumab among 4.420 people 
who have side effects while taking alemtuzumab (FDA report) 
[6]. All patients were middle-aged and treated with 
alemtuzumab for T-cell depletion and multiple myeloma [6]. 
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Corticosteroids, used in alemtuzumab pre-treatment, are well 
known as causing significant cardiovascular side effects [7].  
2. Case Report 
A 24-year-old woman with highly active R-MS was started 
on alemtuzumab 12 mg 1 vial intravenously, after trying 
natalizumab, interrupted after the second administration 
following an allergic reaction, and mitoxantrone (total dose 
reached 120 mg). Among the co-pathologies, we report 
obesity (Body Mass Index 43) and sporadic migraine, not 
under prophylactic treatment. The patient does not smoke and 
does not take the contraceptive pill. All blood and urinary tests 
performed before alemtuzumab were normal except for 
fibrinogen and reactive C protein (CRP) that were slightly 
beyond standard limits. After corticosteroid pre-treatment and 
during the first alemtuzumab administration, the patient 
complained about severe headaches, different from the usual 
one experienced. Considering the headache features, the 
pre-treatment with steroids and the cardiovascular risk 
associated with obesity, D-dimer was dosed. D-dimer resulted 
highly increased (38000 ng/dL). Vital signs revealed blood 
pressure 125/70 mmHg, heart rate of 80 beats per minute, 
body temperature of 37.1°C and oxygen saturation was 97%. 
To exclude cerebral venous thrombosis patient underwent 
brain angio-CT scan, which resulted normal. There were no 
signs of peripheral thrombosis. Arterial blood gas test showed 
mild hypocapnia (28.3 mmHg) and mild hyperoxia (147 
mmHg). Pulmonary perfusion scintigraphy revealed reduced 
tracer uptake in the lingula. this finding was compatible with 
pulmonary thromboembolism. The patient received 
enoxaparin 10000 I. U. subcutaneously. The day after the 
patient underwent a pulmonary angio-CT scan, with no signs 
of thromboembolism, and D-dimer control, which showed a 
reduction (15452 ng/mL). No further doses of alemtuzumab 
were administered. One month before alemtuzumab treatment, 
following the patient’s written consent, we collected serum in 
order to analyze the further change in lymphocytes subset, as 
the patient participated in an immunological study. After this 
adverse event occurred, we used the patient’s serum to detect 
TNF-α, IL-6 and IFN-γ levels. We thus measured that 
cytokines levels also the day of alemtuzumab administration. 
An increase of IL-6 was observed at the time of administration 
(106±11,6 pg/ml) compared to pre-treatment (65±3,1 pg/ml). 
3. Discussion 
Alemtuzumab is an immunosuppressive drug that rapidly 
reduces B and T lymphocytes and is associated with an 
increase of serum proinflammatory cytokines, as IL-6 [3], a 
biomarker of inflammation [8]. IL-6, a circulating cytokine 
produced by monocytes, macrophages, T lymphocytes and 
endothelial cells, plays a central role in the hepatic production 
of CRP, fibrinogen, and other acute-phase proteins involved in 
the inflammatory process [9] and can promote a 
prothrombotic state by increasing expression of fibrinogen, 
tissue factor, factor VIII and von Willebrand factor, as well as 
by activating endothelial cells and increasing platelet 
production [9]. D-dimer is a fibrin degradation product, a 
small protein fragment present in the blood after a blood clot is 
degraded by fibrinolysis; it is not usually present in human 
blood plasma, except when the coagulation system has been 
activated, for instance, because of the presence of thrombosis 
or disseminated intravascular coagulation. D-dimer is also an 
acute-phase reactant whose production stimulates high levels 
of cytokines such as IL-6 that, in turn, may promote neutrophil 
and monocyte activation, inducing the further release of IL-6 
[10]. 
Human Immunodeficiency Virus (HIV)-positivity in the 
adult population, a condition characterized by low 
CD4+lymphocytes similarly to alemtuzumab treatment, 
higher levels of IL-6 and D-dimer are associated with an 
increased risk of cardiovascular disease [11].  
Our patient had also two other cardiovascular risk factors: 
pre-treatment with corticosteroids and severe obesity. Of note, 
an increase of IL-6 was associated with a higher BMI and 
suggested as a marker of inflammation, and endothelial 
dysfunction state in obesity [12]. 
4. Conclusion 
D-dimer test is not necessary during or after alemtuzumab 
therapy, although, its possible increase in a prothrombotic 
status following inflammation as a consequence of 
proinflammatory cytokine release, including IL6, makes it a 
useful biomarker in patients at greater thrombotic risk.  
In an HIV setting, a recent study [13] developed a 
biomarker score (the “IL-6 & D-dimer score”), which 
combines markers of inflammation and coagulation to predict 
the cardiovascular risk among HIV-infected adults. Such a 
score could be an appropriate biomarker to identify possible 
high cardiovascular risk in MS patients before and after first 
alemtuzumab dose, in order to tailor the MS-therapy with 
alemtuzumab, reducing the vascular risk, also considering the 
emerging reports of thrombotic acute episodes during or after 
alemtuzumab treatment [5]. 
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